RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106
RedHill Biopharma’s Talicia Received the US FDA’s Approval for H. pylori in Adults
Shots:
- RedHill regains exclusive WW rights for RHB-106 signed in 2014, encapsulated formulation for bowel preparation
- In 2014, RedHill signed a license agreement with Salix to commercialize RHB-106 in specific territories. RedHill received $7M up front and up to $5M in milestones, plus royalties
- RHB-106 is a flavorless, odorless, solid oral encapsulated formulation P-IIa candidate targeted for cleansing of the gastrointestinal tract prior to the performance of abdominal procedures and diagnostic tests
Click here to read full press release/ article | Ref: RedHill Biopharma | Image: Signbox